Login / Signup

Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.

Soo-Chin LeeJoseph J ZhaoYu Yang SoonAdrian KeeSen Hee TayFolefac AminkengYvonne AngAlvin S C WongLavina D BharwaniBoon Cher GohRoss A Soo
Published in: Cancers (2023)
Using SITC criteria, an elevated NLR (≥3) at 6 weeks, female gender and a later line of immunotherapy treatment (≥2 lines) were predictive factors of developing primary resistance to ICI monotherapy in patients with advanced NSCLC.
Keyphrases
  • advanced non small cell lung cancer
  • epidermal growth factor receptor
  • combination therapy
  • small cell lung cancer
  • tyrosine kinase
  • clinical trial
  • replacement therapy